

## **ANNEXa-I Deep Dive: Part II References**

Special Guests: Scott Dietrich, PharmD, BCCCP  
Brian Gilbert, PharmD, MBA, BCCCP, FCCM, FNCS  
Todd Miano, PharmD, PhD, FCCM

### **Featured Article**

ANNEXA-I Investigators. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. *N Engl J Med*. 2024 May 16;390(19):1745-1755. <https://pubmed.ncbi.nlm.nih.gov/38749032/>

### **Articles Referenced**

Siegel DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. *N Engl J Med*. 2015 Dec 17;373(25):2413-24. <https://pubmed.ncbi.nlm.nih.gov/26559317/>

ANNEXA-4 Investigators. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. *Circulation*. 2023 Mar 28;147(13):1026-1038. <https://pubmed.ncbi.nlm.nih.gov/36802876/>

Siegel D, Lu G, Leeds JM, Karbarz M, Castillo J, Mathur V, Hutchaleelaha A, Sinha U, Kitt M, McClure M, Hollenbach SJ, Curnutte JT, Conley PB, Crowther M. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. *Blood Adv*. 2017 Sep 22;1(21):1827-1838. <https://pubmed.ncbi.nlm.nih.gov/29296829/>

Willekens G, Studt JD, Mendez A, et al. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation. *Br J Haematol*. 2021 Jun;193(6):1203-1212. <https://pubmed.ncbi.nlm.nih.gov/33954979/>

Karaszewski B, Szczyrba S, Jabłoński B, et al. Case report: First treatment of acute ischaemic stroke in a patient on active rivaroxaban therapy using andexanet alfa and rtPA combined with early complete recovery. *Front Neurol*. 2023 Oct 25;14:1269651. <https://pubmed.ncbi.nlm.nih.gov/37965168/>

Dohle DS, Pfeiffer P, Probst C, Treede H. Andexanet alfa and heparin resistance in cardiac surgery: Experiences and risks associated with the reversal of direct oral anticoagulants. *Eur J Cardiothorac Surg*. 2023 Jun 1;63(6):ezad189. <https://pubmed.ncbi.nlm.nih.gov/37144957/>

Nagashima K, Ueki C, Numari J, et al. Andexanet Alfa-Induced Heparin Resistance: Sustained Anticoagulant Inefficacy Despite Antithrombin Therapy. *J Cardiothorac Vasc Anesth*. 2024 Mar 27:S1053-0770(24)00229-5. <https://pubmed.ncbi.nlm.nih.gov/38834448/>

ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. *N Engl J Med*. 2016 Sep 15;375(11):1033-43. <https://pubmed.ncbi.nlm.nih.gov/27276234/>

INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med*. 2013 Jun 20;368(25):2355-65. <https://pubmed.ncbi.nlm.nih.gov/23713578/>

Gómez-Outes A, Alcobilla P, Calvo-Rojas G, et al. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. *J Am Coll Cardiol*. 2021 Jun 22;77(24):2987-3001.

<https://pubmed.ncbi.nlm.nih.gov/34140101/>

Dobesh PP, Fermann GJ, Christoph MJ, et al. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. *Res Pract Thromb Haemost*. 2023 Aug 30;7(6):102192. <https://pubmed.ncbi.nlm.nih.gov/37753225/>

Li Q, Yakhkind A, Alexandrov AW, et al. Code ICH: A Call to Action. *Stroke*. 2024 Feb;55(2):494-505.

<https://pubmed.ncbi.nlm.nih.gov/38099439/>

Goldin M, Smith K, Koulas I, et al. Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors. *TH Open*. 2024 May 13;8(2):e209-e215.

<https://pubmed.ncbi.nlm.nih.gov/38741610/>